Jeff J Jacobs

US Patent:

8138202, Mar 20, 2012

Filed:

Dec 30, 2010

Appl. No.:

12/982785

Inventors:

Anantha Sudhakar - Fremont CA, US
Jeff Jacobs - San Mateo CA, US
Ahmad Hashash - Pleasant Hill CA, US
Sean Ritchie - Fremont CA, US
Hengqin Cheng - Foster City CA, US

Assignee:

Sunesis Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61K 31/4375
A61P 35/00

US Classification:

514300, 546122, 546123

Abstract:

Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.

US Patent:

8586601, Nov 19, 2013

Filed:

Sep 3, 2010

Appl. No.:

12/875927

Inventors:

Anantha Sudhakar - Fremont CA, US
Jeff Jacobs - San Mateo CA, US
Ahmad Hashash - Pleasant Hill CA, US
Sean Ritchie - Fremont CA, US
Hengqin Cheng - Foster City CA, US

Assignee:

Sunesis Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61K 31/4375
A61P 35/00

US Classification:

514300, 546122, 546123

Abstract:

Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.

US Patent:

56080352, Mar 4, 1997

Filed:

Feb 2, 1994

Appl. No.:

8/190788

Inventors:

Stephen D. Yanofsky - San Mateo CA
Ronald W. Barrett - Sunnyvale CA
David N. Baldwin - Palo Alto CA
Jeff W. Jacobs - San Mateo CA

Assignee:

Affymax Technologies N.V. - Middlesex

International Classification:

A61K 3800
A61K 3802
C07K 500
C07K 700

US Classification:

530324

Abstract:

Peptides that bind to the interleukin-1 type I receptor (IL-1RtI) can be used to assay the amount of IL-1R, or an IL-1R agonist or antagonist, in a sample and comprise a sequence of amino acids selected from the group consisting of (1) WXXXGZ. sub. 1 W (SEQ ID NO: 1) where Z. sub. 1 is L, I, A, or Q; (2) XXQZ. sub. 5 YZ. sub. 6 XX (SEQ ID NO: 6) where Z. sub. 5 is P or Aze where Aze is azetidine; and Z. sub. 6 is S, A, V, or L; and (3) Z. sub. 23 NZ. sub. 24 SZ. sub. 25 Z. sub. 26 Z. sub. 27 Z. sub. 28 Z. sub. 29 Z. sub. 30 L (SEQ ID NO: 17) where Z. sub. 23 is D or Y; Z. sub. 24 is D or S; Z. sub. 25 is S or W; Z. sub. 26 is S or Y; Z. sub. 27 is D or V; Z. sub. 28 is S or W; Z. sub. 29 is F or L; and Z. sub. 30 is D or L; and where each amino acid is indicated by standard one letter abbreviation; and each X can be selected from any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids.

US Patent:

57672342, Jun 16, 1998

Filed:

Feb 1, 1995

Appl. No.:

8/383474

Inventors:

Stephen D. Yanofsky - San Mateo CA
Ronald W. Barrett - Sunnyvale CA
David Baldwin - Palo Alto CA
Jeff W. Jacobs - San Mateo CA

Assignee:

Affymax Technologies, N.V. - Greenford

International Classification:

A61K 3800
C07K 500
C07K 700

US Classification:

530327

Abstract:

Peptides that bind to the interleukin-1 type I receptor (IL-1RtI) can be used to assay the amount of IL-1R, or an IL-1R agonist or antagonist, in a sample and comprise a sequence of amino acids selected from the group consisting of (1) WXXXGZ. sub. 1 W (SEQ ID NO: 2) where Z. sub. 1 is L, I, A, or Q; (2) XXQZ. sub. 5 YZ. sub. 6 XX where (SEQ ID NO: 1) Z. sub. 5 is P or Aze where Aze is azetidine; and Z. sub. 6 is S, A, V, or L; and (3) Z. sub. 23 NZ. sub. 24 SZ. sub. 25 Z. sub. 26 Z. sub. 27 Z. sub. 28 Z. sub. 29 Z. sub. 30 L (SEQ ID NO: 313) where Z. sub. 23 is D or Y; Z. sub. 24 is D or S; Z. sub. 25 is S or W; Z. sub. 26 is S or Y; Z. sub. 27 is D or V; Z. sub. 28 is S or W; Z. sub. 29 is F or L; and Z. sub. 30 is D or L; and where each amino acid is indicated by standard one letter abbreviation; and each X can be selected from any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids.

US Patent:

20190084978, Mar 21, 2019

Filed:

Apr 11, 2018

Appl. No.:

15/951061

Inventors:

- South San Francisco CA, US
Jeff Jacobs - San Mateo CA, US
Ahmad Hashash - Pleasant Hill CA, US
Sean Ritchie - Fremont CA, US
Hengqin Cheng - Foster City CA, US

International Classification:

C07D 471/04
A61K 31/4375
C07D 417/04
C07D 417/14

Abstract:

Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.

US Patent:

20170226104, Aug 10, 2017

Filed:

Sep 16, 2016

Appl. No.:

15/267911

Inventors:

- South San Francisco CA, US
Jeff Jacobs - San Mateo CA, US
Ahmad Hashash - Pleasant Hill CA, US
Sean Ritchie - Fremont CA, US
Hengqin Cheng - Foster City CA, US

International Classification:

C07D 471/04
A61K 31/4375

Abstract:

Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.

US Patent:

20140275547, Sep 18, 2014

Filed:

Oct 16, 2013

Appl. No.:

14/055590

Inventors:

- South San Francisco CA, US
Jeff Jacobs - San Mateo CA, US
Ahmad Hashash - Pleasant Hill CA, US
Sean Ritchie - Fremont CA, US
Henggin Cheng - Foster City CA, US

Assignee:

SUNESIS PHARMACEUTICALS, INC. - South San Francisco CA

International Classification:

C07D 471/04

US Classification:

546123

Abstract:

Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.